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Schistosomiasis is a neglected tropical disease rampant in developing countries. Widespread 
chemotherapy is reliant on a single drug, praziquantel, which increases the risk of resistance and 
creates an urgent need for the development of new alternatives for treatment. Fungal 
biotransformation is a well-documented tool in the pharmaceutical synthesis of new drugs. This 
study examined the efficacy of four fungal strains, Cunninghamella elegans (ATCC 9245 and 
ATCC 8688a), Umbelopsis ramanniana, (ATCC 9628) and Yarrowia lipolytica (ATCC 20225), 
in the biotransformation of praziquantel. Colonies were cultured, dosed with praziquantel, 
incubated for 5, 10 or 15 days to metabolize, after which the cultures were filtered, metabolites 
extracted and subjected to HPLC analysis. Once the optimal time for metabolization was 
ascertained cultures were exposed to variable drug doses, either single or double. C. elegans, 
ATCC 8688a, fully metabolizes praziquantel after 15 days producing major peaks at 4.7 and 4.3 
minutes; and responded more efficiently to a double dose. After 15 days C. elegans, ATCC 
9245, had metabolized the majority of praziquantel producing major peaks at 4.7 and 4.3 
minutes, and was equally efficient with an increased dose. U. ramanniana, fully metabolizes 
praziquantel after 10 days producing major peaks at 4.9 and 4.5 minutes, however, failed to 
produce metabolites with increased dosage. Y. lipolytica, showed negligible metabolic activity. 
The praziquantel peak remained relatively unchanged at 8.1 minutes for each time course and 
was not exposed to variable doses. Purification of the mixture and further testing is required to 
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Schistosomiasis, also referred to as bilharzia, is largely a disease of poverty; particularly 
prevalent in tropical areas such as sub-Saharan Africa, (Hotez, et al., 2014). Schistosomiasis is 
caused by blood flukes, Schistosoma sp., of which there are five primary species. S. mansoni 
primarily located in the Africa, the Arabian Peninsula, and South America. Whilst it is also 
found in rodents and non-human primates, humans remain its main host. S. haematobium is 
commonly found in Africa and the Arabian Peninsula. S. japonicum is a zoonotic parasite 
capable of infecting humans and 40 other mammalian reservoirs, located throughout China and 
South East Asia, (Ross , et al., 2002).  S. intercalatum and S. mekongi also cause schistosomiasis 
but are confined to smaller areas and deemed only of local significance.  
It is the second most commonly contracted parasitic disease after malaria; affecting 
approximately 207 million people, (Meister, et al., 2014). 120 million of these are symptomatic 
and 20 million have contracted a severe form of schistosomiasis. It is estimated that 85% of 
those infected reside on the African continent in undeveloped regions. South America is also 
heavily infested; Brazil cites schistosomiasis as the one of the top three public health problems, 
(Chitsulo, et al., 2000). As such schistosomiasis bears a significant burden, both economically 
and in terms of public health. The disability adjusted life years lost for schistosomiasis is ~70 
million, annually; this is akin to HIV and exceeds both malaria and tuberculosis, (King & 
Dangerfield-Cha, 2008). 
In recent years there has been a relative hiatus in the continued research of 
schistosomiasis treatment, characterisation, and eradication. Given the low level of investment 
for the continued research into treatment and prevention of schistosomiasis, this disease is often 





A pyrazino-isoquinoline derivative, praziquantel, PZQ, has proven most effective against 
schistosomiasis, (Woelfle, et al., 2011). The combination of being readily available and cost 
effective has quickly made it the preferred drug for the wide spread chemotherapy of 
schistosomiasis, (Alsaqabi & Lofty, 2014). Once ingested praziquantel shows results in less than 
an hour. It works by damaging the tegument of the worms which causes paralysis. After a single 
treatment 70-100% of patients cease to excrete eggs; those that still do exhibit a decrease of 
viable eggs and associated antigen concertation by 95%, (Gryseels & Polderman, 1991). 
However, there are significant drawbacks with the praziquantel treatment. Firstly, it is ineffective 
against eggs and juvenile Schistosoma sp.. Additionally, tissue dwelling eggs can be excreted 
several weeks after treatment. Therefore, a second dose of the treatment is required 4-6 weeks 
after the first, which many patients fail to acquire, (Renganathan & Cioli, 1998) . Additionally, 
praziquantel is administered as a racemate mixture, however, the anthelmintic activity is only 
associated with the R-(-)-enantiomer, (Schepmann & Blaschke, 2001). Whereas the S-(-)-
enantiomer is biologically inactive and the causation of many side effects linked to the treatment. 
It is estimated that 80% of the drug is excreted in urine, (Alsaqabi & Lofty, 2014).  
Such a heavy reliance on a single treatment and drug with wide spread use exponentially 
increases the inherent risk of resistance and tolerance by Schistosoma sp., (Woelfle, et al., 2011). 
Drug resistance and tolerance in disease causing organism is on the rise, (Valentim, et al., 2013). 
Whilst, as yet, there is no documented cases for wide spread PZQ resistance in Schistomiasis sp.. 
There is evidence of resistance mechanisms that researchers have identified in laboratory isolates 
which show significantly reduced susceptibility to PZQ, (Couto, et al., 2011). Moreover, it is 
possible to induce PZQ resistance to S. mansoni and S. japonicum in vivo, (Wang, et al., 2012). 





increased tolerance to treatment has presented itself in the field. S. mansoni of many foci have 
sowed reduced susceptibility. S. haematobium has also been documented causing infections in 
which repeated standard treatment fails to eradicate. Treatment failure of other infections can be 
as high as 30%, (Wang, et al., 2012). In the absence of an effective vaccine for human helminth 
infections, repetitive rounds of monotherapies are used, however these increase the risk of both 
resistance and tolerance, (Taylor, et al., 2017) . Therefore, there is an urgent need to identify and 
synthesise new PZQ derivatives in order to circumvent this and other drawbacks to the current 
treatment, (Vale, et al., 2017). 
Fungal biotransformation is a widely established model to investigate drug metabolism 
and produce metabolites in vitro, (Dube & Kumar, 2017). The fungal biotransformation of 
organic compounds is well-documented as a useful tool in the pharmaceutical synthesis of new 
drugs, (Parshikov, et al., 2012).  It is frequently used in lieu of chemical synthesis and other 
transformation techniques, (Rui, et al., 2005). The experimental procedures for fungal 
biotransformation offers many advantages; it is relatively simple and has the capacity to be 
scaled up far beyond other methodologies whilst remaining cost effective, (Moody, et al., 2002). 
This study offers a viable procedure for obtaining PZQ derivatives. Where the 
introduction of modifiable moiety, via fungal biotransformation, can vastly increase the 
opportunity for derivation of the original structure; possibly be used as a scaffold for the 
production of novel semi-synthesized compounds. These compounds maybe able to meet the 
urgent needs to synthesize new derivatives and drug analogs in order to mitigate the risks of drug 
resistance and tolerance. 
Methodology   






 Four fungal strains were selected for this investigation. Cunninghamella elegans, ATCC 
9245, the most frequently used strain in fungal biotransformation, and Cunninghamella elegans, 
ATCC 8688a, for comparison. Cunninghamella sp. are zygomycete fungi studied extensively for 
their biotransformation capability and their metabolic similarities to humans, (Pothuluri, et al., 
1998).  Cunninghamella sp. expose compounds to diverse metabolic pathways, including region- 
and stereo selective mechanisms, (Moody, et al., 2002), leading to the creation of novel 
metabolites, (Zhang, et al., 1996). Previous studies cite C. elegans as the most efficient 
Cunninghamella sp, (Moody, et al., 2002).  
Umbelopsis ramanniana, ATCC 9628, previously referred to as Mucor ramannianus, are 
saprobic fungi, (Parshikov, et al., 1999), which have been used in the biotransformation of 
several compounds, (Kang, et al., 2008).  U. ramanniana has shown promising results of 
metabolising other quinolones, (Sutherland, et al., 2005). It is equally efficient in the production 
of derivatives as C. elegans, and also used for its similarities to mammalian metabolism, 
(Parshikov, et al., 2000).   
Yarrowia lipolytica, ATCC 20225, is a hemiascomycetous dimorphic fungus that is 
showing increasing promise in the biotransformation of various industrially important 
compounds, particularly in processes that involve hydroxylation, (Bankar, et al., 2009). 
Additionally, Y. lipolytica shows similar efficacy to U. ramanniana and is particularly efficient 
at bio-catalysing hydrophobic compounds, of which PZQ is one, (Fickers, et al., 2005). 
Culturing and biotransformation  
Using a modified protocol derived from Parshikov, et al., 2004, triplicate cultures of 
fungal mycelia were cultured for 48 (h) in 125 ml of HiMedia, Yeast-Mold, (YM) broth medium. 





to two experimental conditions. Initially, the optimal time courses were investigated in order to 
establish a baseline for the comparison of subsequent experimental runs with differing drug 
doses. After the initial 48 (h) of culturing 40mg/ml of PZQ, suspended in acetone, was added to 
the broth culture. Where upon cultures were left for a period of 5, 10, or 15 days before 
metabolite extraction. Secondly, dose comparison was carried out.  After the initial 48 (h) of 
culturing either 40mg/ml, single dose, or 80mg/ml, double dose, of PZQ were added to the 
cultures; which were then left to metabolize for a number of days as dictated by the results of 
time courses.  
Extraction and purification of metabolites 
After metabolization the mycelia was filtered using a buchner funnel and filter paper, 
with a 20 to 25μm particle retention, washed with water and discarded. Metabolites were 
separated from the retained culture broth via extraction using three equal volumes of 100ml ethyl 
acetate, Fisher Scientific, EtOAc, and evaporated in vacuum, using a BUCHI rotavapor R II 
connected to a BUCHI V-700 Vacuum Pump. High-performance liquid chromatography was 
used to ascertain if, and how much, PZQ has been metabolized. The evaporated samples were 
dissolved in Acetonitrile and run through a Dionex UltiMate 3000 HPLC System for a total of 20 
minutes. Broken down as a gradient starting at 20% acetonitrile in 2% acetic acid to 100% 
acetonitrile in 16 minutes, followed by 100% acetonitrile for 2 minutes, then reducing to 20% 
acetonitrile in the final 2 minutes. Injection of 10uL of samples were run through a PRP-1 guard 
column and a Waters X-terra RP8 3.5μm column. This reverse phase column holds onto the less 
polar molecules for a longer amount of time within the column. Therefore, in the chromatograms 





Quantification of HPLC 
Four standard solutions of PZQ dissolved in acetone were prepared at 1mg/mL, 0.75 
mg/mL, 0.5 mg/mL, and 0.1 mg/mL. These standards were run alongside the filtrate samples 
from the dose courses. During post analysis of chromatogram peaks area under the curve was 
calculated and compared to the standards and the amount of un-metabolized PZQ given.  
 Statistics 
One-way t-tests were run to determine the effect of substrate concentration on overall 
metabolite production, using R version 3.5.2, to see the significance of the differences between 
the quantitative HPLC results of unmetabolized PZQ during the dose comparisons, and to 
ascertain if those differences were significantly greater or lesser. 
Results 
When compared to both the control of PZQ, Fig 1A, and each fungi strain without PZQ, 
Fig 1 B-D, HPLC chromatograms demonstrate that both C. elegans species and U. ramanniana, 
ATCC 9628, were capable of metabolizing the parent molecule of PZQ. However, the metabolic 
activity Y. lipolytica, ATCC 20225 was negligible. The subsidiary peaks, assumed to be 
metabolites, were considered insignificant when proportionally compared to the parental 
praziquantel peaks, Fig 2. Thus, once the time courses were conducted Y. lipolytica was retired 








Figure 1: Chromatogram of controls A) Praziquantel, B) C. elegans, ATCC 8668a, C) C. 
elegans, ATCC 9245, D) U. ramanniana. Arrows indicate where PZQ would peak on the 









Cunninghamella elegans, ATCC 8668a 
HPLC chromatograms indicate that after ten days the peak indicating PZQ is near null, 
and on day 5 is considerably reduced, Fig 3. Thus, 1 days was identified as the most efficient 
metabolization time to yield maximum metabolites. Profiles of C. elegans ATCC 8668a show 
two major subsidiary peaks assumed to correspond to metabolites. These occur at 4.3 and 4.7 
minutes, Fig 4, and are not seen in either of the controls, Fig 1A and 1B. comparing 
chromatograms from the dose courses, Fig 5, there was a significant difference, p = 0.0063, in 
the means of unmetabolized PZQ between single dose, 40mg/ml, and double dose, 80mg/ml, 
Figure 2:  5, 10, and 15 day chromatograms of Y. lipolytica cropped around the peak 
representing PZQ to show time course trends and comparison. Difference deemed 
negligible Arrows indicate peak corresponding to unmetabolized PZQ. 





groups. Double dose left an average of 0.4 mg/mL unmetabolized, compared to those cultures 
given a single dose, 0.9 mg/mL, Table 1. 
Cunninghamella elegans, ATCC 9245 
As with the previous strain, C. elegans, ATCC 9245, HPLC chromatogram profiles 
indicate two major subsidiary peaks also occurring a 4.3 and 4.7 minutes, Fig 6, and again are 
not seen in either of the controls, Fig 1A and 1C. Fifteen days was considered optimal with the 
peak indicating PZQ being considerably smaller when compared to the other days, Fig 7. When 
exposed to a double dose of PZQ the strain showed similar efficacy and metabolic activity 
producing the same metabolites as a single dose. Under both conditions the fungi left a similar 
mean of PZQ left unmetabolized, 0.299mg/mL for single dose and 0.195mg/mL for double, 
Table 1. Additionally, there are 3 further subsidiary peaks, at 5.8, 6.3 and 6.7 minutes, that 
become more pronounced at a double dose, when compared to the chromatogram of single dose, 
Fig 8. The statistics did show a significant variance between the means but not a significant 
difference, p = 0.058. 
Umbelopsis ramanniana, ATCC 9628 
U. ramanniana yielded similar results following the trends of both C. elegans strains. At 
a single dose of PZQ U. ramanniana, the peak for PZQ was reduced to the base line after 10 
days, Fig 9, producing peaks assumed to be metabolites at 4.5 and 4.9 minutes, Fig 10. However, 
the fungi appeared to fail to respond to a double dose of PZQ, 11. The differences between the 
mean amount of unmetabolized PZQ between single dose and double dose groups was not shown 





























Day 5 Day 15 Day 10* 
Figure 3: 5, 10, and 15 day chromatograms of C. elegans, ATCC 8668a, cropped around the peak 
representing PZQ to show time course trends and comparison. Day 10 shown to be optimal. Arrows 
indicate peak corresponding to unmetabolized PZQ 
 
Figure 4: Full spectrum chromatogram 
for the metabolites produced after 10 
days metabolization by C. elegans, 
ATCC 8668a. Arrows indicate peak 
corresponding to unmetabolized PZ, 
brackets surround major peaks assumed 
to indicate predominant metabolites, 4.3 




























Figure 5: Chromatograms of the dose treatment for C. elegans, ATCC 8668a, A) double dose, 80mg/ml, 
B) single dose, 40mg/ml. Arrows indicate the peak representing the unmetabolized PZQ. The brackets 
highlight the area that the peaks assumed to be the major metabolites occur. Differing styles between 
chromatograms reflect analytical technique. A) tested strictly for PZQ, B) full spectrum of peaks. 
Figure 6: Full spectrum 
chromatogram for the metabolites 
produced after 15 days metabolization 
by C. elegans, ATCC 9245. Arrows 
indicate peak corresponding to 
unmetabolized PZ, brackets surround 
major peaks assumed to indicate 






















Both strains of C. elegans were able to fully degrade PZQ and produce metabolites. 
Cytochrome P450 enzymes are paramount to the metabolism of many medications including 
PZQ, (Lynch & Price, 2007). It is unanimous in mammals and found in many fungal strains such 
as C. elegans. Many investigations have demonstrated that humans, and more basal mammals 
such as rats, are able to metabolize PZQ, (Meier & Blaschke, 2001), therefore it was expected 
that the two C. elegans strains tested would also be able to metabolize PZQ. 
Whilst both C. elegans strains produce major metabolites with the same peaks, 4.3 and 
4.7 minutes, there are comparative differences in activity of the two strains. C. elegans ATC 
8668a is able to fully metabolize PZQ in 10 days, in contrary to the 15 exhibited by C. elegans  
Day 5 Day 15* Day 10 
Figure 7: 5, 10, and 15 day chromatograms of C. elegans, ATCC 9245, cropped around the peak 
representing PZQ to show time course trends and comparison. Day 15 shown to be optimal. Arrows 




















ATC 9245.  When considering the chromatograms of the time course for C. elegans ATC 9245 
after 15 days the peak indicating PZQ is not completely flush to the base line. However, it is still 
deemed the optimal amount of time to allow for the most efficient metabolization. It is possible 
that leaving the strain for longer, such as 20 days, would yield a more complete metabolization 
of PZQ. However, when comparing peak height trends displayed by the chromatograms, Fig 7, 
that of day 15 is considerably smaller than the other two time points, specifically between day 10 
and 15 where the greatest reduction is observed. Additionally, it is thought that the peak height is 
already nominal and that by allowing extra time for metabolism would serve to increase the 
overall timeline for metabolite production for minimal product gain. Therefore, in order to  
A B 
Figure 8: Chromatograms of the dose treatment for C. elegans, ATCC 9245, A) double dose, 
80mg/ml, B) single dose, 40mg/ml. Arrows indicate the peak representing the unmetabolized PZQ. 
The brackets annotated with a, *, highlight the area that the peaks assumed to be the major metabolites 
occur, the second set reflect the occurrence of a second set of metabolites occurring more prominently 
in A. Differing styles between chromatograms reflect analytical technique. A) tested strictly for PZQ, 





























Day 5 Day 15 Day 10* 
Figure 9: 5, 10, and 15 day chromatograms of U. ramanniana, cropped around the 
peak representing PZQ to show time course trends and comparison. Day 10 shown to 
be optimal. Arrows indicate peak corresponding to unmetabolized PZQ 
Figure 10: Full spectrum chromatogram for the 
metabolites produced after 15 days metabolization 
by U. ramanniana. Arrows indicate peak 
corresponding to unmetabolized PZ, brackets 
surround major peaks assumed to indicate 
















Table 1: Summary table of statistical analysis demonstrating the means between the single and 







Cunninghamella elegans, ATCC 
8688a 0.973 0.44 0.006 
Cunninghamella elegans, ATCC 
9245 0.299 0.195 0.058 
Umbelopsis ramanniana, ATCC 
9628 0.404 3.857 Insignif. 
 
preserve methodic efficiency 15 days was decided to be optimal. Another interesting observation 
was that occurrence of three additional subsidiary peaks on the chromatogram at double dose. 
Whilst these metabolite peaks are seen under single dose conditions, they are far more 
pronounced and distinct from the surrounding “noise’ under double dose. This implies that these 
A B 
Figure 11: Chromatograms of the dose treatment for C. elegans, ATCC 8668a, A) double dose, 
80mg/ml, B) single dose, 40mg/ml. Arrows indicate the peak representing the unmetabolized PZQ. 





peaks represent additional minor, in the terms of this study, metabolites. Moreover, 
proportionally these peaks appear to increase greater than the major metabolic peaks with an 
increase in dose. This may indicate that C. elegans, ATCC 9245, may be able to produce more 
metabolites than C. elegans, ATCC 8668a. This may mean that it produces more drug analogues 
which may make it the preferable C. elegans strain despite longer needed for optimal 
metabolization. 
  In the dose course assays, C. elegans ATCC 8668a shows a significant difference 
between the single and double doses administered. These differences suggest that at a double 
dose C. elegans ATCC 8668a is more efficient. Presenting a lower mean of unmetabolized PZQ 
suggests it is able to utilize and metabolize at a higher rate than at a single dose. This was an 
unexpected result; one possible explanation is the increased dose saturates the culture medium 
more efficiently than at a single dose allowing higher surface area contact between mycelia and 
drugs allowing them to metabolize a greater volume of PZQ.  The means for c. elegans, ATCC 
9245, were not shown to be significantly different and it can be concluded that, based on the 
similar means the averages of two groups are significantly similar. It is therefore likely that the 
strain is just as efficient at metabolizing a double dose of the drug solution as a single dose. 
At a single dose of PZQ U. ramanniana, acted similar to C. elegans, ATCC 8668a, 
reducing PZQ effectively after ten days. This result was also expected as many biotransformation 
investigations use the two strains in comparative studies, usually yielding similar results. 
Additionally, although not explicitly studied, U. ramanniana is thought to contain the 
cytochrome P450 based on an study conducted by Antoniou,  et al., 1994. The investigation 
studied azole inhibition concluded that this provides evidence that the hydroxylases are 





metabolites or reduce the amount of PZQ. Additionally, the mean amount of PZQ unmetabolized 
was both higher than the single dose and higher than the original amount added to the cultures. 
Initially this appears to be an anomalous result. However, when comparing the chromatograms 
from the fungi to the control of PZQ the peaks representing PZQ from the fungi appear to be 
much wider, Fig 12. Doubling the dose of PZQ also includes doubling the volume of solvent 
added to the culture medium. This increase in acetone may not be conducive to organism growth 
and retard mycelial metabolism. Thus, yielding metabolites which do not represent a complete 
degradation of the parent model. Such metabolites maybe considered incomplete and not be 
distinct in their polarity form the original structure. Thus, do not differentiate themselves enough 
to form their own distinct HPLC peak. This would cause a false positive and the resulting 
chromatogram peak to widen and the analysis to calculate a greater amount of PZQ. 
Previous experiments examining the biotransformation of PZQ have not directly used 
Yarrowia lipolytica , therefore it was unknown how it would react. Yarrowia lipolytica presents 
both oxygenases and hydroxylases, which along with other enzymes degrades hydrophobic 
substrates very efficiently, (Bankar, et al., 2009), and give the fungi great potential for the 
production of various biochemicals and intermediates, (Spagnuolo, et al., 2018). However, in this 
investigation Y. lipolytica was not able to significantly metabolize PZQ or produce metabolites; 
surprising given the hydrophobic nature of PZQ, (Mainardes & Evangelista, 2005). However, 
studies utilizing the strains often focus on the byproducts of metabolic processes rather than the 
metabolites. Those that are targeting the bio transformation or degradation of a compound often 
use lipids and other organic oils and fatty acids as targets, (Bankar, et al., 2009). It is therefore 
possible that the lack of success with PZQ is due to utilizing the fungi for the incorrect 





lipolytica as a tool for screening its efficacy with certain compounds often cite that peak 
metabolic efficiency is correlated to specific medium parameters, particularly those that are 
nutrient limited. Most conclude that there is considerable selection of suitable strains with the 
desired properties needed to find the most suitable strain for the needs, (Kim, et al., 2007). 
Therefore, again it could be that despite its proven efficacy with other compounds and its 






Figure 6:  Comparison of PZQ 
peaks across dose treatments after 
10 days of metabolization by U. 
ramanniana. Peaks aligned on 
solid red line by the maximum 
height of peaks. The top 
chromatogram indicates U. 
ramanniana dosed with 
40mg/mL, the proceeding 
chromatograms were dosed with 
80mg/mL. Dashed green lines 
indicate the upper and lower 
bounds of the PZQ peak at a 
single dose demonstrating the 
difference in widths between the 






The results of this study further provide evidence of fungal strains practicality in the 
biotransformation of compounds and drugs. In addition to providing a targeted methodology for 
specific strains when used in conjunction to PZQ; demonstrating the efficacy of both C. elegans 
and U. ramanniana. Those strains which were successful in their metabolization are thought to 
have introduced modifiable moiety increasing the opportunity for derivatization of the original 
structure. However, in order to verify this the chemical structures of the derivatives must be 
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